Exploring the potential of isatin hybrids as anticancer agents: recent advances and future prospective

IF 3.1 4区医学 Q3 CHEMISTRY, MEDICINAL

Medicinal Chemistry Research Pub Date : 2025-02-17 DOI:10.1007/s00044-025-03385-6

Parveen Gahlyan, Tanisha Chauhan, Priyanka Jhajharia, Balaram Pani, Rakesh Kumar

{"title":"Exploring the potential of isatin hybrids as anticancer agents: recent advances and future prospective","authors":"Parveen Gahlyan, Tanisha Chauhan, Priyanka Jhajharia, Balaram Pani, Rakesh Kumar","doi":"10.1007/s00044-025-03385-6","DOIUrl":null,"url":null,"abstract":"<div><p>Synthesis of hybrid molecules via molecular hybridization technique has been known to be a promising strategy which involves the blending of two pharmacophoric groups joined via covalent bonds to make a single entity that can serve as chemotherapeutic agents. “Isatin” is an important toolbox for medicinal chemists with high pharmacological profile being known as the “privileged scaffold” in the field of drug development. Various drugs consisting of isatin core have been shown to have pronounced therapeutic effects on several cancers as they have prophylactic role towards free radicals that cause cancer. This report highlights the most recent advances from the past four years in the development of isatin based drugs against several human cancer cell lines such as MCF-7 (breast cancer cell line), A-549 (lung cancer cell line), Hep-G2 (liver cancer cell line) and some other cell lines, respectively.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"34 4","pages":"827 - 848"},"PeriodicalIF":3.1000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicinal Chemistry Research","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00044-025-03385-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Synthesis of hybrid molecules via molecular hybridization technique has been known to be a promising strategy which involves the blending of two pharmacophoric groups joined via covalent bonds to make a single entity that can serve as chemotherapeutic agents. “Isatin” is an important toolbox for medicinal chemists with high pharmacological profile being known as the “privileged scaffold” in the field of drug development. Various drugs consisting of isatin core have been shown to have pronounced therapeutic effects on several cancers as they have prophylactic role towards free radicals that cause cancer. This report highlights the most recent advances from the past four years in the development of isatin based drugs against several human cancer cell lines such as MCF-7 (breast cancer cell line), A-549 (lung cancer cell line), Hep-G2 (liver cancer cell line) and some other cell lines, respectively.

Abstract Image

查看原文本刊更多论文

探索isatin杂交体作为抗癌药物的潜力：最新进展和未来展望

通过分子杂交技术合成杂交分子已被认为是一种很有前途的策略，它涉及到两个药效基团通过共价键连接在一起，形成一个单一的实体，可以作为化疗药物。“Isatin”是药物化学家的重要工具箱，具有很高的药理学形象，被称为药物开发领域的“特权支架”。由isatin核心组成的各种药物已被证明对几种癌症有明显的治疗效果，因为它们对导致癌症的自由基有预防作用。本报告重点介绍了过去四年来针对几种人类癌细胞系（如MCF-7（乳腺癌细胞系）、A-549（肺癌细胞系）、Hep-G2（肝癌细胞系）和其他一些细胞系）的以isatin为基础的药物开发的最新进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medicinal Chemistry Research 医学-医药化学

CiteScore

4.70

自引率

3.80%

发文量

162

审稿时长

5.0 months

期刊介绍： Medicinal Chemistry Research (MCRE) publishes papers on a wide range of topics, favoring research with significant, new, and up-to-date information. Although the journal has a demanding peer review process, MCRE still boasts rapid publication, due in part, to the length of the submissions. The journal publishes significant research on various topics, many of which emphasize the structure-activity relationships of molecular biology.